[Pubmed] Multiple Autoimmune Complications After a Single Dose of Pembrolizumab

[RSS-Bot]

Cureus. 2023 Mar 7;15(3):e35871. doi: 10.7759/cureus.35871. eCollection 2023 Mar.

ABSTRACT

Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.

PMID:37033516 | PMC:PMC10079282 | DOI:10.7759/cureus.35871


Source: https://pubmed.ncbi.nlm.nih.gov/3703351 ... t6+86293ac